Nuveen Credit Opportunities 2022 Target Term Fund JCO 深 沪
等待开盘 10-08 09:30:00 美东时间
7.95
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 7.95
- 总市值 2.21亿
- 52周最高 8.2547
- 市盈率 静 25.06
- 换手率 0.00%
- 52周最低 7.7787
- 委 比 0.00%
- 总股本 2777.44万
- 历史最高 8.9727
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.3067
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多复宏汉霖HLX22治疗胃癌的头对头III期临床完成阿根廷首例患者给药
内容来源：复宏汉霖 2025年9月23日，复宏汉霖宣布，公司新表位HER2单抗HLX22头对头对比一线标准疗法（曲妥珠单抗+化疗±帕博利珠单抗）的国际多中心I...
09-23 20:21
In Vivo与Allo CAR-T：谁先攻克商业化堡垒？
（来源：抗体圈） 2020年前后，同种异体CAR-T（AlloCAR-T）疗法风头无两。作为传统自体CAR-T的升级方向，它承诺摆脱“一人一药”的定制化...
09-22 18:46
Tempus Validates PurIST Algorithm To Guide First-Line Treatment And Improve Outcomes In Advanced Pancreatic Cancer
Real-world evidence demonstrates PurIST's ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC)Tempus AI, Inc. (NASDAQ:TEM), a technology
09-09 20:37
Bajaj Consumer Care Announces Equity Share Buyback
An announcement from Bajaj Consumer Care Limited ( ($IN:BAJAJCON) ) is now avai...
09-03 00:45
Chemours, DuPont, and Corteva Agree to $875M PFAS Settlement Spanning 25 Years
Settlement payments will total $875 million over a 25-year period beginning within 30 days of the Judicial Consent Order ("JCO") entry date, which will be no earlier than January 1, 2026. Of the total settlement amount,
08-04 18:47
利普卓联合阿比特龙和泼尼松或泼尼松龙在华获批用于治疗BRCA突变的转移性去势抵抗性前列腺癌患者
这一批准基于PROpel III期临床试验结果，相较阿比特龙单药治疗，利普卓联合疗法将疾病进展或死亡风险降低76% 上海2025年7月31日 /美通社/ --...
07-31 15:33
京东旗下京东链已注册 JCOIN 及 JOYCOIN，或为旗下稳定币名称
据明报报道，京东旗下京东币链已注册 “JCOIN” 及 “JOYCOIN”，市场普遍认为这两个名称将用作其稳定币。报道称，相关服务涵盖通过区块链技术提供电子...
07-29 14:48
全球研发 | 挑战全球一线治疗，复星医药子公司复宏汉霖HLX22头对头III期临...
2025年7月14日，复星医药子公司复宏汉霖（2696.HK）宣布，公司创新型抗HER2单抗HLX22头对头对比一线标准疗法（曲妥珠单抗+化疗±帕博利珠单抗）的...
07-15 17:53
Verastem's Ovarian Cancer Trial Results Published In Journal Of Clinical Oncology, Titled "Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer"; Verastem's Avutometinib Combo Shows 31% Overall Response Rate In Ovarian Cancer Trial
Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose cancer had progressed after multiple prior lines of therapyThe majority of patients (82%) had
07-12 04:15
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., Jun...
06-30 21:00
